Issue: October 2018
September 15, 2018
3 min watch
Save

VIDEO: New treatment option for rare cardiomyopathy may 'change lives'

Issue: October 2018
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

MUNICH — In this Cardiology Today video exclusive, Martha Gulati, MD, MS, FACC, FAHA, offers her highlights from the European Society of Cardiology Congress, including the ATTR-ACT and SCOT-HEART trials.

ATTR-ACT, which showed tafadamis (Pfizer) improved outcomes in patients with certain types of transthyretin amyloid cardiomyopathy, is the trial from ESC Congress “that I think is going to change lives the most,” Gulati, division chief of cardiology for the University of Arizona College of Medicine – Phoenix and physician executive director for the Banner – University Medicine Heart Institute, told Cardiology Today.

Gulati also provides her insight on the SCOT-HEART trial, which showed that patients with stable chest pain who underwent CTA with standard care had lower CV outcomes at 5 years compared with standard care alone.

“This is a controversial study that we’ll keep discussing,” she said.

Watch the video for more.